Literature DB >> 964287

Pharmacokinetics of diazepam in disordered liver function.

P B Andreasen, J Hendel, G Greisen, E F Hvidberg.   

Abstract

The plasma elimination curves of diazepam following intravenous administration of 10 mg were studied in nine patients with cirrhosis of the liver and four patients without liver disease. The data were analyzed according to a two compartment model. The mean biological half-life (T/2) of diazepam was increased five-fold in patients with cirrhosis compared to the controls (164 hours vs. 32.1 hours). The plasma clearance of diazepam could be correlated neither with a quantitative measure of liver function, as estimated by galactose elimination capacity, nor to semiquantitative measures of liver function, such as serum albumin and prothrombin. It is suggested that the plasma clearance of diazepam is an inaccurate index of its rate of hepatic metabolism due to the complex kinetics of the drug.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 964287     DOI: 10.1007/BF00609469

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  The effect of spironolactone on antipyrine metabolism in man.

Authors:  D H Huffman; D W Shoeman; P Pentikäinen; D L Azarnoff
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

2.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

3.  Plasma half-life of phenylbutazone in patients with impaired liver function.

Authors:  E F Hvidberg; P B Andreasen; L Ranek
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

4.  Pharmacokinetics of diazepam in dogs, mice and humans.

Authors:  E van der Klejin; J M van Rossum; E T Muskens; N V Rijntjes
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

5.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

6.  The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man.

Authors:  P D Thomson; M Rowland; K L Melmon
Journal:  Am Heart J       Date:  1971-09       Impact factor: 4.749

7.  Phenazone metabolism in patients with liver disease.

Authors:  P B Andreasen; G Greisen
Journal:  Eur J Clin Invest       Date:  1976-01-30       Impact factor: 4.686

8.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

9.  Determination of the hepatic elimination capacity (Lm) of galactose by single injection.

Authors:  N Tygstrup
Journal:  Scand J Clin Lab Invest Suppl       Date:  1966

10.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

View more
  23 in total

Review 1.  Sedation for fibreoptic bronchoscopy.

Authors:  M P Shelley; P Wilson; J Norman
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

4.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

5.  Pharmacokinetics of intravenous anaesthetics: implications for clinical use.

Authors:  M M Ghoneim; K Korttila
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

6.  Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects.

Authors:  F B Eatman; W A Colburn; H G Boxenbaum; H N Posmanter; R E Weinfeld; R Ronfeld; L Weissman; J D Moore; M Gibaldi; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 7.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

8.  Neuropsychologic effects of diazepam related to single dose kinetics and liver function.

Authors:  J Hendel; P Elsass; P B Andreasen; E Gymoese; E F Hvidberg
Journal:  Psychopharmacology (Berl)       Date:  1976-07-09       Impact factor: 4.530

9.  Sedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis.

Authors:  N A Hamdy; H J Kennedy; J Nicholl; D R Triger
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.